Skip to content

Study · Not a test of the peptide alone · 2026

10 results

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Verma S, Böttcher M, Brown P, Dicker D, Rubino D, Sbraccia P, Sharma AM, Smedegaard L, Sørrig R, Garvey WT

Hypertension (Dallas, Tex. : 1979)2 Dec 2025Cited by 4 (Europe PMC)

PMID41328546 (opens in a new tab)PMCIDPMC12822771 (opens in a new tab)DOI10.1161/hypertensionaha.125.26055 (opens in a new tab)PepBankPUB-41328546
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome

    In adults with resistant hypertension at baseline, the proportion reaching blood pressure targets at week 68 was 42.0% with CagriSema and 29.3% with placebo, with a confidence interval that included 1.

    In plain wordsIn adults with resistant hypertension, 42.0% on CagriSema and 29.3% on placebo reached blood pressure targets; the difference was not clearly shown.

    Peptide
    Cagrilintide
    Outcome
    No significant changeProportion with resistant hypertension reaching BP targets at week 68
    Study

    n = 167

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Participants reaching BP targets
    42%
    CagriSema, resistant hypertension
    Participants reaching BP targets
    29.3%
    placebo, resistant hypertension
    Odds ratio
    1.7 ratio
    resistant hypertension

    Source sentences

    Summary
    The proportion of participants with resistant hypertension at baseline (n=167) that reached BP targets at week 68 was 42.0% and 29.3% for CagriSema and placebo, respectively (odds ratio, 1.7 [95% CI, 0.7-4.4]).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  2. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with resistant hypertension at baseline, the proportion reaching blood pressure targets at week 68 was 42.0% with CagriSema and 29.3% with placebo; the odds ratio confidence interval included 1.

    In plain wordsIn adults with resistant high blood pressure, 42.0% on the CagriSema combination and 29.3% on placebo reached targets; the difference was not clearly shown.

    Peptide
    Semaglutide
    Outcome
    No significant changeProportion reaching blood pressure targets in participants with resistant hypertension
    Study

    n = 167

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Proportion at BP target
    42%
    CagriSema, resistant hypertension
    Proportion at BP target
    29.3%
    placebo, resistant hypertension
    Odds ratio
    1.7 ratio
    CagriSema vs placebo

    Source sentences

    Summary
    The proportion of participants with resistant hypertension at baseline (n=167) that reached BP targets at week 68 was 42.0% and 29.3% for CagriSema and placebo, respectively (odds ratio, 1.7 [95% CI, 0.7-4.4]).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and no diabetes, systolic blood pressure fell more with CagriSema than with placebo at week 68 (-10.9 versus -2.8 mm Hg).

    In plain wordsIn adults with overweight or obesity, CagriSema lowered systolic blood pressure more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseChange in systolic blood pressure at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Systolic BP change
    −10.9 mm Hg
    CagriSema
    Systolic BP change
    −2.8 mm Hg
    placebo

    Source sentences

    Summary
    Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 04HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and no diabetes, diastolic blood pressure fell more with CagriSema than with placebo at week 68 (-5.4 versus -1.7 mm Hg).

    In plain wordsIn adults with overweight or obesity, CagriSema lowered diastolic blood pressure more than placebo.

    Peptide
    Cagrilintide
    Outcome
    DecreaseChange in diastolic blood pressure at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Diastolic BP change
    −5.4 mm Hg
    CagriSema
    Diastolic BP change
    −1.7 mm Hg
    placebo

    Source sentences

    Summary
    Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  5. 05HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and no diabetes, more participants reached blood pressure targets at week 68 with CagriSema than with placebo (63.0% versus 32.0%).

    In plain wordsIn adults with overweight or obesity, more people reached blood pressure targets with CagriSema (63.0%) than with placebo (32.0%).

    Peptide
    Cagrilintide
    Outcome
    IncreaseProportion reaching blood pressure targets at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Participants reaching BP targets
    63%
    CagriSema
    Participants reaching BP targets
    32%
    placebo

    Source sentences

    Summary
    The proportion of participants reaching BP targets at week 68 was 63.0% and 32.0% for CagriSema and placebo, respectively.
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  6. 06HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome

    Among participants using antihypertensive medication, more decreased or stopped treatment with CagriSema than with placebo (39.6% versus 18.8%).

    In plain wordsAmong people taking blood pressure drugs, more cut down or stopped them with CagriSema (39.6%) than with placebo (18.8%).

    Peptide
    Cagrilintide
    Outcome
    IncreaseDecrease or stop of antihypertensive medication
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Participants decreasing or stopping treatment
    39.6%
    CagriSema
    Participants decreasing or stopping treatment
    18.8%
    placebo

    Source sentences

    Summary
    Among participants who used antihypertensive medication during the study, 39.6% in the CagriSema group decreased or stopped treatment from week 0 to week 68 versus 18.8% with placebo.
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  7. 07HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, CagriSema (semaglutide plus cagrilintide) lowered systolic blood pressure more than placebo at week 68.

    In plain wordsIn adults with overweight or obesity, CagriSema, a semaglutide and cagrilintide combination, lowered systolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure change from baseline to week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Systolic BP change
    −10.9 mm Hg
    CagriSema
    Systolic BP change
    −2.8 mm Hg
    placebo

    Source sentences

    Summary
    Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, CagriSema (semaglutide plus cagrilintide) lowered diastolic blood pressure more than placebo at week 68.

    In plain wordsIn adults with overweight or obesity, CagriSema, a semaglutide and cagrilintide combination, lowered diastolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiastolic blood pressure change from baseline to week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Diastolic BP change
    −5.4 mm Hg
    CagriSema
    Diastolic BP change
    −1.7 mm Hg
    placebo

    Source sentences

    Summary
    Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively).
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 09HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, a higher proportion reached blood pressure targets at week 68 with CagriSema (semaglutide plus cagrilintide) than with placebo.

    In plain wordsIn adults with overweight or obesity, more people reached blood pressure targets with the CagriSema combination than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion reaching blood pressure targets at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Proportion at BP target
    63%
    CagriSema
    Proportion at BP target
    32%
    placebo

    Source sentences

    Summary
    The proportion of participants reaching BP targets at week 68 was 63.0% and 32.0% for CagriSema and placebo, respectively.
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  10. 10HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    Among participants who used antihypertensive medication, more decreased or stopped treatment with CagriSema (39.6%) than with placebo (18.8%).

    In plain wordsAmong people on blood pressure medicine, more cut back or stopped it on the CagriSema combination than on placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseDecrease or stop of antihypertensive medication from week 0 to week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Decreased or stopped antihypertensive treatment
    39.6%
    CagriSema
    Decreased or stopped antihypertensive treatment
    18.8%
    placebo

    Source sentences

    Summary
    Among participants who used antihypertensive medication during the study, 39.6% in the CagriSema group decreased or stopped treatment from week 0 to week 68 versus 18.8% with placebo.
    1 context sentence
    Summary · context
    The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 3NCT05567796

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Novo Nordisk A/Sn = 3,4001 Nov 2022 to est. 19 Oct 2026

Obesity

Trial pageClinicalTrials.govUpdated 30 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.